{"id":"W4406869312","doi":"10.1200/jco.2025.43.4_suppl.448","title":"Updated results from the trastuzumab deruxtecan (T-DXd) 5.4 mg/kg triplet combination of DESTINY-Gastric03 (DG-03): First-line (1L) T-DXd with fluoropyrimidine (FP) and pembrolizumab in advanced/metastatic HER2-positive (HER2+) esophageal adenocarcinoma, gastric cancer (GC), or gastroesophageal junction adenocarcinoma (GEJA).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre hospitalier universitaire de Québec","funders":"","keywords":"Pembrolizumab; Medicine; Trastuzumab; Metastatic melanoma; Cancer research; Gemcitabine; Nivolumab; Internal medicine; Oncology; Cancer; Immunotherapy; Melanoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002320677,0.0005177124,0.002524409,0.0006955593,0.0001621428,0.00004149715,0.0004299529,0.0003103028,0.0001521203],"category_scores_gemma":[0.002618509,0.0003309771,0.0003646152,0.00159713,0.0004665979,0.0003381285,0.0001609961,0.001610506,0.000003454878],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008629601,"about_ca_system_score_gemma":0.002268167,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001217867,"about_ca_topic_score_gemma":0.002696636,"domain_scores_codex":[0.9931179,0.0008160183,0.003924361,0.0006927155,0.0008225011,0.0006264765],"domain_scores_gemma":[0.9916183,0.003751807,0.003018143,0.000448687,0.0008054236,0.0003575797],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1092116,0.00276504,0.7394183,0.000188775,0.001432632,0.00204971,0.0004931301,0.001395044,0.0000610481,0.00006001278,0.005734584,0.1371901],"study_design_scores_gemma":[0.06293907,0.01974525,0.9106925,0.0006302384,0.002218857,0.0003306975,0.000636631,0.001652871,0.000115646,0.0002450916,0.0006035632,0.0001896364],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.982434,0.002945381,0.00182254,0.01014843,0.0009924085,0.001234444,0.0001191156,0.00002928477,0.0002743918],"genre_scores_gemma":[0.9907557,0.001524589,0.00518271,0.001272938,0.0004940641,0.00004199581,0.0001119174,0.00004530073,0.0005707378],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1712742,"threshold_uncertainty_score":0.9999142,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0508744364437234,"score_gpt":0.3738558524944282,"score_spread":0.3229814160507048,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}